Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …

Importance The prognosis for patients with pancreatic cancer is poor, even after resection
with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced …

Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …

Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …

Chemotherapy sometimes can cause potential tumor-specific T-cell-mediated immune
response via stimulating immunogenic cell death (ICD). However, such immune response is …

The cytosine analogues 5‐azacytosine (azacytidine) and 2′‐deoxy‐5‐azacytidine
(decitabine) are the currently most advanced drugs for epigenetic cancer therapies. These …

Silymarin contains a group of closely-related flavonolignan compounds including silibinin,
and is extracted from Silybum marianum species, also called milk thistle. Silymarin has been …

Cancer is the second leading cause of death affecting nearly one in two people, and the
appearance of new cases is projected to rise by> 70% by 2030. To effectively combat the …

BACKGROUND & AIMS: The human equilibrative nucleoside transporter (hENT1) protein
transports gemcitabine into cells. Small retrospective studies in pancreatic cancer suggest …